For 2017, New Jersey's largest insurer made particularly good progress in certain diabetes measures and in cancer screenings.
New Jersey’s largest health insurer has reported a 10% jump in value-based payments to physicians for 2017, driven in part by more cancer screenings and fewer trips to the emergency department for people with diabetes.
Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced total payments were $104 million, on top of fee-for-service payments. These payments covered savings for episodes of care, contracts with accountable care organizations (ACOs), and the OMNIA Health Alliance, which are long-term relationships that Horizon has 6 large health systems in the state.
In its statement, Horizon noted that 70% of its in-network primary care physicians are involved in some type of value-based program. That share has climbed 20% over the past 2 years. In an appearance last week with the Institute of Value-Based Medicine, a program of The American Journal of Managed Care®, Horizon BCBSNJ Executive Vice President for Healthcare and Transformation Management Allen Karp said that more than 1000 specialists, including oncologists, also take part in value-based programs, and that some will take part in “prospective” models come January 1, 2019.
“Horizon began engaging doctors in value-based care collaborations nearly a decade ago and these results confirm that it is our members—their patients—who benefit most when we create a strong partnership and work as a team to provide the care they need,” Karp said in a statement. “The question is no longer whether to pursue value-based partnerships, it is which models deliver the best quality improvements, the best patient experience and are most effective at lowering an individual’s total cost of care.”
Overall, members who received care from value-based care providers produced a 4% lower total cost of care trend compared with all commercial members. Horizon also reported that members who providers in value-based programs had a 4% lower rate of hospital inpatient admissions, a 6% higher rate of colorectal cancer screenings, and a 7% higher rate of breast cancer screenings.
In particular areas that drive healthcare costs, including patients with diabetes, the results were even better. Compared with the entire commercial membership, patients seeing value-based providers experienced:
According to Thomas R. Graf, MD, Horizon BCBSNJ chief medical officer and vice president for healthcare transformation, the calculations also adjusted for demographic, socioeconomic, and health risk factors, as well as the effect of high-cost outliers.
“The better outcomes and lower costs demonstrate that a health insurer like Horizon can have a very different kind of relationship with its network doctors and hospitals, and that working together fulfills our common commitment to do what is best for our patients and members,” Graf said.
Research Points to Potential MCIDs in Diabetes Distress Scale–17
November 29th 2023Researchers identified a value of at least 0.25 to be a minimal clinically important difference (MCID) in diabetes distress, and MCID values of 0.38 and 0.39 for emotional and interpersonal distress subscales and physician and regimen distress subscales, respectively.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
In this interview with The American Journal of Managed Care®, Katie Queen, MD, addresses the complexity of obesity as a medical condition, pivoting to virtual care while ensuring that patients who lived in a rural location continued to receive adequate care, and the importance of integrating awareness of obesity and chronic disease prevention into local food culture.
Read More
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen